ProBioGen, a Contract Development and Manufacturing Organisation (CDMO) and technology provider with expertise in cell line engineering, process development and GMP manufacturing, has appointed Alfrez Merz as CEO, effective May 1, 2024.
He follows Dr Lutz Hilbrich as interim CEO, who is leaving at his own request by a mutual termination agreement.
Dr Alfred Merz joins from Bayer Pharmaceuticals where he held the position of Senior Vice President & Head of Product Supply Medical Devices. Alfred has more than 30 years international experience in manufacturing, operational excellence and strategy development with leading pharmaceuticals and biotech- companies including Bayer and Novartis in Europe and the US.
Dr Lutz Hilbrich joined the company as CEO of ProBioGen AG in June 2020 and is also CEO of its subsidiary MiGenTra GmbH.
Dr. Wafik Bardissi, Chair of the Supervisory Board of ProBioGen AG and CEO and Chair of the parent Company Minapharm commented: “Alfred‘s strategic vision and proven international track record ln Europe and the USA in driving operational excellence, manufacturing and strategy development make him an ideal candidate to prop up ProBioGen’s next phase of innovation and expansion.“
